Understanding how hormone receptors are broken down in cancer
Official title: Characterizing a Common Degradation Pathway for Nuclear Hormone Receptors
Funded at Brigham and Women's Hospital · NIH-10933400 · Data updated 2026-11-12
This study is looking at how certain proteins in our body, which are important for the development of common cancers like breast and prostate cancer, are broken down after they interact with hormones, and it aims to find ways to create better treatments that target these proteins.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 22, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $447,500 |
| NIH project number | 5DP5OD036132-02 |
| Project ID | NIH-10933400 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast or prostate cancer who are being treated with hormone-targeting therapies.
✕Less likely to help
Patients with cancers unrelated to hormone receptor signaling may not benefit from this research.
What this research studies
This research investigates the degradation pathway of nuclear hormone receptors (NRs), which are crucial in the development of common cancers like breast and prostate cancer. By examining how these receptors are broken down after hormone binding, the study aims to uncover the mechanisms that regulate their activity. The research employs biochemical techniques to identify the role of specific proteins, such as the UBR5 ligase, in the degradation process. This understanding could lead to improved therapies that target these receptors more effectively.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hormone-related cancers by enhancing the targeting of nuclear hormone receptors.
How similar studies have gone: Previous research has shown success in targeting nuclear hormone receptors in cancer treatment, indicating that this approach has potential for meaningful advancements.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Tsai, Jonathan Michael — Brigham and Women's Hospital
- Study coordinator: Tsai, Jonathan Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.